Targeting the PI3K/AKT/mTOR pathway with small-molecule inhibitors is an emerging field in bladder cancer (Liu et al., 2018; Sathe and Nawroth, 2018). The gene discussed is AKT1; the disease is urinary bladder carcinoma.